2009 DIA US Annual Meeting GCP Session Advisory Committee Meeting

Slides:



Advertisements
Similar presentations
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Advertisements

Pharmaceutical Congress Spring 2003 Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers Michael P. Swiatocha June 8, 2003.
„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“
© Clinical Research Practice Clinical Research Organization and Management 1.
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
Cheryl McCarthy Manager, Quality Assurance MBC Session October 3, 2008 GCP Compliance in our Vendors.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
Special Topics in IND Regulation
Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.
External Quality Assessments
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Internal Auditing and Outsourcing
GIQAR Annual Congress 25 – 26 th May Pv QA: Quality Assurance for Pharmacovigilance Allison Jack Manager, R&D Oversight – GCP/PV, Pfizer Ltd BARQA.
CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Regulatory Overview.
Chesapeake Research Review, Inc. Human Research Protection Experts IRB Services Consultation Education 1 Holding External IRBs Accountable: An Independent.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.
Module J Audits and Inspections Patricia E. Koziol 1Module J Final Version 1-May-2010.
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Yale Center for Clinical Investigation: Academic Home to the CTSA Secretary’s Advisory Committee on Human Research Protections (SACHRP) Presentation Tesheia.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
Regulators’ response to consultation on EU legislative proposals for pharmacovigilance : common themes 2 nd International Pharmaceutical Regulatory and.
Belinda Seto, Ph.D. Acting Deputy Director for Extramural Research National Institutes of Health Human Subjects Research Enhancements Awards Renaissance.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Special Program for Internal/Compliance Audit Professionals: Enterprise Risk.
Agenda for Session Compliance in Clinical Research
Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.
Office of Human Research Protection Georgia Health Sciences University.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Chapter 17 Internal and Value-Added Auditing. Internal Auditing DEFINED Internal auditing is an independent and objective assurance and consulting activity.
Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs September.
Using Australian Clinical Sites – Challenges for International Sponsors Prof A J (Tony) Webber Clinical Network Services Pty Ltd Brisbane, Australia.
Department of Health and Human Services1 Update: October 2006 Public Meeting on Emergency Research Diane Maloney, J.D. Associate Director for Policy FDA.
Establishment of Medical Device GMP Requirements Hsiau-Wen Huang, Ph. D. Senior Researcher Bureau of Pharmaceutical Affairs Department of Health.
EUPATI Training Course Patient Experts in Medicines Research & Development The project is receiving support from the Innovative Medicines Initiative Joint.
GCP (GOOD CLINICAL PRACTISE)
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.
Paper Destruction Team Full Team Meeting 9 April 2013.
Responsibilities of Sponsor, Investigator and Monitor
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Briefing on MHRA routine inspection of non-commercial clinical trials
“Your sustainable compliance and remediation partners”
FDA's Two New Draft Guidance on Software and Device
A capacity building programme for patient representatives
June | Philadelphia, PA Pennsylvania Convention Center
Track 11 Symposium 27 June :30 – 3:00 PM
Responsibilities of Sponsor, Investigator and Monitor
Nordic Cooperation on Ethical Review Procedures Nordforsk – nordic trial alliance MIKA SCHEININ
2009 DIA US Annual Meeting GCP Session Advisory Committee Meeting
Updating the Regulation for the JINR Programme Advisory Committees
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
Director, Asia Pacific Japan and U.S. Clinical Operations
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
DIA Clinical Safety and Pharmacovigilance Community
The Current PMA Requirements
Introduction to Quality Risk Management in GCP
US Early Feasibility Studies (EFS)
Quality System.
Combination products The paradigm shift
PhUSE Computational Science
Timothy B. Cleary, Esq. Meredith Manning, Esq.
Presentation transcript:

2009 DIA US Annual Meeting GCP Session Advisory Committee Meeting 24 April 2008

Agenda Review Committee roles Review Process for selecting sessions Review 2008 Sessions Review 2009 Session Theme, Call for abstracts and Session Ideas Brainstorm additional ideas 4/24/2008

Advisory Committee Role Bring Ideas for session themes, chairs and speakers Review session topic lists and provide input Submit session abstracts 4/24/2008

2009 Session Mega Tracks 3 MEGA TRACKS What is a Mega Tracks? A mega track is where multiple tracks are encouraged to develop sessions within their interest area but also collaborate to eliminate overlap of similar session topics and promote broader discussion and fuller understanding of the topics presented. Advertising/Marketing/Medical Communications MegaTrack New for 2009! AD – Advertising, MA – Marketing, MC - Medical Communications Clinical Research MegaTrack AHC/IS-Academic Health Centers/Investigator Sites New for 2009! CR - Clinical Research and Development/Clinical Supplies New for 2009! OS – Outsourcing, PM/FI-Project Management/Finance Information Technology MegaTrack EC-eClinical, ERS/DM – Electronic Regulatory Submissions/Document Management, CDM - Clinical Data Management, IT - Information Technology, VA – Validation 4/24/2008

2009 Session Tracks 22 “Standard” Tracks BT-Biotechnology CMC/GMP - Chemistry, Manufacturing and Controls CP - Clinical Safety and Pharmacovigilance GCP - Good Clinical Practices IMP/EBM - Impact (Impact of Medical Products and Therapies)/Evidence-Based Medicines MW - Medical Writing NC - Nonclinical Laboratory Safety Assessment   NHP - Natural Health Products PP - Public Policy/Law RA - Regulatory Affairs RD - R&D Strategy ST - Statistics TR – Training 4/24/2008

Task List Call for Abstracts: Ask for sessions that are in line with our theme and topic ideas Evaluate 2008 Sessions Recruit Session Chairs Review abstracts submitted Organize by session topic Meet with other session chairs Finalize selections 4/24/2008

2008 GCP Track Theme Do Disclosure, compliance, auditing and QA Activities add value and improve patient safety and data integrity? 4/24/2008

2008 Session List 4/24/2008

2008 Call for Session Abstracts GCP - Good Clinical Practices The topics/issues related to the good clinical practices aspects of both global and local clinical trials, including internal QA programs and audit outcomes, regulatory inspection results and processes (FDA, EMEA, other countries, comparison of FDA and EMEA), discussion of the latest issues in the clinical trial process including impact of new developments in GCP to speed up the clinical trial process, human subject protection issues such as informed consent and IRB/ethics committee procedures, compliance and oversight of clinical trials, use of electronic systems in clinical trials, including validation and audit of these systems, detection and prevention of fraud and misconduct in clinical trials, financial aspects of clinical trials, GCP inspections, training of investigators, IRBs, and industry personnel, auditing practices and techniques, and discussion of evolving international clinical trial disclosure law and guidance and effects on the clinical trial life cycle. 4/24/2008

2009 GCP Track Theme Do Disclosure, compliance, auditing and QA Activities add value and improve patient safety and data integrity? Modify Theme? 4/24/2008

2009 Session Topic Ideas Session # 2009 Session Topic Idea 1 Are auditors really independent? Can they pass the test? 2 Off-shoring: how to tackle and address the quality management challenges 3 Are we learning from our mistakes? A review of recent FDA inspection findings. 4 Who should evaluate Vendor Qualifications? Company functional team vs QA? 5 Challenges of auditing in emerging countries 6 The Auditor as consultant: Terminate that site! 7 Clinical Trial Disclosure: Does it really inform the patients? 8 Is my company compliant with Clinical Trial Disclosure Law? 9 Review of Regulatory Agency Audit Reports 10 Does the audit program really contribute to enhanced quality and patient protection? 11 12 13 4/24/2008

2009 Call for Session Abstracts Keep same write up? Update to be more directed in request? 4/24/2008

Points to Consider for Sessions Audience level Basic or Advanced? Town Halls Debates; present different points of view and discuss? Panel discussions? Law updates/discussions 4/24/2008

Discussion 4/24/2008